Neuroone Medical Technologies (NasdaqCM:NMTC) Conference September 17, 2025 12:15 PM ET Company ParticipantsRon Mcclurg - CFODave Rosa - President, CEO & DirectorNoneWith CEO Dave Rosa and CFO Ron McClurg of NeuroOne Medical Technologies Corporation, ticker NMTC. During the presentation, please feel welcome to submit questions using the Zoom Q&A interface at the bottom of your screen. After the presentation, we'll open to your questions. With that, Dave, I'll turn it over to you.Dave RosaAll right. Thanks, ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.It pays to be patient, especially when it comes to buying durable Dividend Aristocrats that have stood the test of time when they are attractively valued. Do ...

We came across a bullish thesis on DexCom, Inc. on Flyover Stocks Substack by Todd Wenning. In this article, we will summarize the bulls’ thesis on DXCM. DexCom, Inc.'s share was trading at $76.22 as of September 12th. DXCM’s trailing and forward P/E were 53.68 and 29.41 respectively according to Yahoo Finance. Best Diabetes Stocks to Buy Now DexCom (DXCM) is a leading provider of continuous glucose monitoring (CGM) devices, serving millions of people managing Type 1 and Type 2 diabetes, as well as indiv ...

We came across a bullish thesis on Align Technology, Inc. on Flyover Stocks’s Substack by Todd Wenning. In this article, we will summarize the bulls’ thesis on ALGN. Align Technology, Inc.'s share was trading at $131.56 as of September 12th. ALGN’s trailing and forward P/E were 22.22 and 12.24 respectively according to Yahoo Finance. Kalcutta/Shutterstock.com Align Technologies (ALGN) is the company behind Invisalign, a clear plastic alternative to traditional metal braces, and is headquartered in Tempe ...

Watch the “What This Means” segment here MINNEAPOLIS, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company delivering fluid management solutions for critically ill patients, today announced that it participated in a Virtual Investor “What This Means” segment. For the segment, Ryan Marthaler, Vice President of Product Marketing & Business Development of Nuwellis, discussed the Company’s recent news release announcing that the National Institutes of Health (NIH) has ...

Key Takeaways GEHC launched Voluson Performance 18 and 16 to advance maternal and reproductive care.GEHC's new AI-driven tools cut exam time by up to 75% and improve imaging precision.GEHC's Voluson systems earned FDA and CE approvals, supporting global rollout later this year.GE HealthCare (GEHC) recently unveiled the Voluson Performance 18 and 16, the latest generation of ultrasound systems in its women’s health portfolio. The launch underscores the company’s commitment to advancing maternal and reproduct ...

Key Points The company has a nearly 50-year history of annual dividend raises. Yet, the medical device maker is not usually flagged as a dividend stock. 10 stocks we like better than Medtronic › The list of Dividend Kings -- the very few U.S.-traded stocks that have enacted dividend raises at least once annually for a minimum of 50 years in a row -- is extremely short. That's why it's quite an event when a new stock joins this very limited and exclusive club. Barring a sudden collapse of its busin ...

并购交易 - STAAR Surgical Company与Alcon达成最终合并协议 Alcon将以每股28美元现金价格收购STAAR [1] - STAAR董事会一致认为该合并符合公司及股东最佳利益 强烈建议股东投票支持合并提案 [1] - 特别股东大会将于2025年10月23日上午8:30以虚拟方式举行 旨在通过合并协议 [1] 交易背景与估值依据 - 公司认为Alcon提供的估值超过STAAR作为独立实体在可预见未来所能实现的价值 [1] - 决策基于STAAR较低的增长率及其对估值产生的负面影响 [1] - 公司面临服务市场的重大竞争和宏观挑战 [1] 区域市场风险 - 业务高度集中于中国市场 该地区面临显著经济不确定性 [1] - 尽管公司已采取应对措施 但中国区销售趋势仍持续下滑 [1]

LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating childr ...

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent’s new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysi ...